Bern M M, Green J
Thromb Res. 1982 Aug 15;27(4):457-65. doi: 10.1016/0049-3848(82)90063-9.
Despite the suppressive effects of uremia upon platelet function, patients with chronic renal failure are at increased risk for thrombotic diseases. This increased risk is linked to lowered concentrations of antithrombin III (AT III) and increased platelet release in vivo, as indicated by increased plasma concentrations of platelet factor 4 (PF4). Sulfinpyrazone, a drug capable of reducing the frequency of thrombotic events in uremic patients, allows return toward normal of the AT III while reducing to normal the plasma concentration of PF4. Thus, suppression of platelet function by sulfinpyrazone appears to reduce in vivo clotting, and thus reduces consumption of AT III.
尽管尿毒症对血小板功能有抑制作用，但慢性肾衰竭患者发生血栓性疾病的风险增加。这种风险增加与抗凝血酶III（AT III）浓度降低以及体内血小板释放增加有关，血小板因子4（PF4）血浆浓度升高表明了这一点。磺吡酮是一种能够降低尿毒症患者血栓形成事件发生率的药物，它可使AT III恢复正常，同时使PF4血浆浓度降至正常。因此，磺吡酮对血小板功能的抑制似乎可减少体内凝血，从而减少AT III的消耗。
